Jeffrey Fudin

Prescribers and pharmacists in various clinical roles are often challenged when treating patients with comorbid chronic pain and end-stage renal disease (ESRD) or hemodialysis (HD). There is a dearth of clinical guidelines available for chronic pain management in this setting. Those selecting pharmacotherapy for patients must rely on clinical judgement, literature analysis and prudent decision making.

A recent New England Journal of Medicine publication addressed the rising costs of naloxone, but failed to address many of the hidden issue that are buried within routine pharmacy practice. Here we unveil some of the less obvious reasons and offer software solutions to help pharmacists safe lives.